Charm Therapeutics raised $80M Series B round co-led by New Enterprise Associates and SR One, w/ OrbiMed, F-Prime Capital, Khosla Ventures, and NVIDIA
02 August 2025
02 August 2025
Total investments received (USD): 130M
Round value (USD): 80M
Company: Charm Therapeutics
Related deals
Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
Investments
07 March 2026
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Chemify in a $50 million equity deal series B Extension backed by Zeon ventures from Japan
Investments
14 February 2026
Encord raised a $60M Series C led by Wellington Management, joined by YC, CRV, N47, Crane Venture, Harpoon, Bright Pixel Capital, and Isomer Capital
Investments
06 February 2026
Tenpoint Therapeutics raises $85M series B with Janus Henderson Investors, Hillhouse Investment, EQT and British Business Bank
Investments
30 January 2026
Belgium
Netherlands
Austria
Germany
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Spain